Scots_NN2 clinical_JJ trial_NN1 out_RP to_TO give_VVI older_JJR people_NN more_RGR muscle_NN1 
Participants_NN2 will_VM be_VBI tested_VVN on_II muscle_NN1 strength_NN1 ,_, muscle_NN1 size_NN1 ,_, daily_JJ function_NN1 and_CC quality_NN1 of_IO life_NN1 over_II the_AT year_NNT1 ._. Picture_NN1 :_: Esme_NP1 Allen_NP1 
A_AT1 Scots-led_JJ clinical_JJ trial_NN1 is_VBZ to_TO examine_VVI whether_CSW a_AT1 commonly_RR used_JJ heart_NN1 pill_NN1 and_CC a_AT1 food_NN1 supplement_NN1 could_VM improve_VVI the_AT health_NN1 of_IO older_JJR people_NN across_II the_AT UK_NP1 by_II improving_VVG muscle_NN1 strength_NN1 ._. 
Researchers_NN2 at_II the_AT University_NP1 of_IO Dundee_NP1 ,_, University_NP1 of_IO Aberdeen_NP1 and_CC Imperial_JJ College_NP1 London_NP1 are_VBR testing_VVG whether_CSW the_AT treatments_NN2 can_VM prevent_VVI the_AT weakening_NN1 of_IO muscles_NN2 that_DD1 commonly_RR affects_VVZ the_AT elderly_NN ._. 
The_AT research_NN1 team_NN1 aims_VVZ to_TO recruit_VVI 450_MC people_NN aged_JJ 70_MC and_CC over_RP from_II across_II the_AT UK_NP1 ._. 
Participants_NN2 will_VM be_VBI given_VVN a_AT1 heart_NN1 pill_NN1 (_( perindopril_NN1 )_) or_CC a_AT1 matching_JJ dummy_NN1 tablet_NN1 ,_, and_CC also_RR a_AT1 food_NN1 supplement_NN1 powder_NN1 (_( leucine_NN1 )_) or_CC matching_JJ dummy_NN1 powder_NN1 ._. 
All_DB the_AT participants_NN2 will_VM take_VVI part_NN1 for_IF a_AT1 year_NNT1 ,_, and_CC the_AT research_NN1 team_NN1 will_VM test_VVI how_RRQ muscle_NN1 strength_NN1 ,_, muscle_NN1 size_NN1 ,_, daily_JJ function_NN1 and_CC quality_NN1 of_IO life_NN1 change_VV0 over_II the_AT year_NNT1 ._. 
Dr_NNB Miles_NP1 Witham_NP1 ,_, lead_NN1 researcher_NN1 for_IF the_AT study_NN1 at_II the_AT University_NP1 of_IO Dundee_NP1 said_VVD :_: "_" Muscle_NN1 weakness_NN1 ,_, which_DDQ we_PPIS2 call_VV0 sarcopenia_NN1 ,_, is_VBZ really_RR common_JJ as_CSA we_PPIS2 get_VV0 older_JJR ,_, and_CC I_PPIS1 see_VV0 many_DA2 patients_NN2 in_II my_APPGE work_NN1 as_II a_AT1 geriatrician_NN1 who_PNQS are_VBR affected_VVN by_II this_DD1 problem_NN1 ._. 
"_" Older_JJR people_NN with_IW weak_JJ muscles_NN2 find_VV0 it_PPH1 much_RR harder_JJR to_TO get_VVI around_RP ,_, or_CC to_TO climb_VVI stairs_NN2 ,_, and_CC are_VBR more_RGR prone_JJ to_II falling_VVG and_CC injuring_VVG themselves_PPX2 ._. In_II the_AT long_JJ term_NN1 ,_, people_NN with_IW weaker_JJR muscles_NN2 are_VBR more_RGR likely_JJ to_TO need_VVI help_NN1 to_TO look_VVI after_II themselves_PPX2 ._. So_RR keeping_VVG muscles_NN2 working_VVG well_RR is_VBZ important_JJ in_II keeping_VVG older_JJR people_NN active_JJ and_CC independent_JJ ._. 
"_" Although_CS we_PPIS2 know_VV0 exercise_NN1 helps_VVZ to_TO improve_VVI muscle_NN1 strength_NN1 even_RR in_II very_RG old_JJ people_NN ,_, it_PPH1 's_VBZ important_JJ to_TO find_VVI new_JJ ways_NN2 to_TO keep_VVI muscles_NN2 working_VVG well_RR in_II older_JJR people_NN and_CC to_TO help_VVI improve_VVI strength_NN1 when_RRQ muscles_NN2 are_VBR weak_JJ ._. 
"_" That_DD1 's_VBZ why_RRQ we_PPIS2 are_VBR excited_JJ to_TO be_VBI running_VVG this_DD1 new_JJ trial_NN1 ._. Previous_JJ research_NN1 has_VHZ suggested_VVN that_CST both_RR perindopril_NN1 and_CC leucine_NN1 might_VM improve_VVI muscle_NN1 strength_NN1 ,_, and_CC both_DB2 these_DD2 treatments_NN2 have_VH0 been_VBN used_VVN safely_RR in_II older_JJR people_NN for_IF many_DA2 years_NNT2 ._. 
"_" It_PPH1 is_VBZ only_RR by_II doing_VDG this_DD1 big_JJ trial_NN1 that_CST we_PPIS2 will_VM really_RR know_VVI if_CSW these_DD2 treatments_NN2 are_VBR going_VVGK to_TO benefit_VVI older_JJR people_NN though_RR ._. "_" 
The_AT Â£_NNU 1.4_MC million_NNO trial_NN1 ,_, named_VVN Lace_NP1 ,_, is_VBZ run_VVN by_II Tayside_NP1 Clinical_JJ Trials_NP2 Unit_NP1 and_CC is_VBZ funded_VVN by_II the_AT Efficacy_NP1 and_CC Mechanism_NP1 Evaluation_NP1 Programme_NP1 ,_, a_AT1 Medical_JJ Research_NP1 Council_NP1 and_CC National_JJ Institute_NP1 for_IF Health_NP1 Research_NP1 partnership_NN1 ._. 
The_AT research_NN1 team_NN1 are_VBR collaborating_VVG with_IW doctors_NN2 at_II 15_MC centres_NN2 across_II the_AT UK_NP1 ,_, and_CC results_NN2 from_II the_AT trial_NN1 are_VBR expected_VVN in_II 2019_MC ._. 
Meanwhile_RR ,_, a_AT1 new_JJ study_NN1 suggests_VVZ that_CST eating_VVG more_DAR apples_NN2 ,_, oranges_NN2 ,_, bananas_NN2 ,_, grapes_NN2 and_CC kale_NN1 could_VM help_VVI teenagers_NN2 and_CC young_JJ women_NN2 reduce_VVI the_AT risk_NN1 of_IO breast_NN1 cancer_NN1 in_II later_JJR life_NN1 ._. 
The_AT study_NN1 ,_, published_VVN in_II the_AT British_JJ Medical_JJ Journal_NP1 ,_, found_VVD high_JJ fruit_NN consumption_NN1 during_II adolescence_NN1 was_VBDZ associated_VVN with_IW a_AT1 25_MC per_NNU21 cent_NNU22 lower_JJR risk_NN1 of_IO breast_NN1 cancer_NN1 diagnosed_VVN in_II middle_JJ age_NN1 ._. 
